Maxim Group Keeps Their Buy Rating on Joint (JYNT)

By Ryan Adsit

Maxim Group analyst Anthony Vendetti reiterated a Buy rating on Joint (JYNTResearch Report) yesterday and set a price target of $25.00. The company’s shares closed last Monday at $19.15.

According to, Vendetti is a 3-star analyst with an average return of 1.2% and a 44.4% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Milestone Scientific, Restoration Robotics, and Ellex Medical Lasers.

Joint has an analyst consensus of Moderate Buy, with a price target consensus of $24.00, representing a 15.4% upside. In a report issued on November 5, B.Riley FBR also reiterated a Buy rating on the stock with a $23.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $21.80 and a one-year low of $6.51. Currently, Joint has an average volume of 135K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

The Joint Corp. (United States) engages in the development, ownership, operation, support and management of chiropractic clinics. It operates through two segments: Corporate Clinics and Franchise Operations. The Corporate Clinics segment comprises of the operating activities of the company owned or managed clinics.